Revenue (Tables)

9 Months Ended

Sep. 30, 2023

Revenue

Schedule of revenue recognized from collaborative arrangements

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2023		2022		2023		2022
Viatris collaboration agreement - Amounts receivable from Viatris	$	15,687	$	12,445	$	39,841	$	34,010

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2023		2022		2023		2022
YUPELRI net sales (Theravance Biopharma implied 35%)	$	20,414	$	18,698	$	56,111	$	51,158

Schedule of collaborative amounts were recorded in the Company's condensed consolidated statements of operations

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2023		2022		2023		2022
Viatris	$	6	$	6	$	18	$	18
Alfasigma		—		—		—		169
Total collaboration revenue	$	6	$	6	$	18	$	187

Summary of the reductions to R&D costs related to reimbursement payments

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2023		2022		2023		2022
Viatris	$	1,340	$	1,657	$	5,041	$	4,736